Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial.
Tadaaki NishikawaKosei HasegawaKoji MatsumotoMasahiko MoriYasuyuki HirashimaKazuhiro TakeharaKazuya AriyoshiTomoyasu KatoShigehiro YagishitaAkinobu HamadaMamiko KawasakiSatoshi KawashimaSawako TomatsuriYukari NagasakaHiroshi YoshidaRyunosuke MachidaAkihiro HirakawaKenichi NakamuraKan YonemoriPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Trastuzumab deruxtecan has efficacy in patients with UCS, regardless of HER2 status. The safety profile was generally consistent with that previously reported. Toxicities were manageable with appropriate monitoring and treatment.